The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals with Obesity
NCT ID: NCT06189001
Last Updated: 2025-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2024-01-01
2024-09-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women
NCT01513499
Oxytocin Effects on Food Motivation Pathways
NCT02276677
Endocrine and Neural Control of Eating in Women
NCT02994420
A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
NCT05664516
Neurotensin - an Important Regulator of Appetite in Humans?
NCT03522792
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin
Intravenous oxytocin 0.2 IU/minute for 300 minutes Approx. 500 ml
Oxytocin
Intravenous oxytocin 0.2 IU/min during experimental days
Placebo
intravenous saline (0.9% NaCl) infusion for 300 minutes Approx. 500 ml
Placebo (saline)
Intravenous saline during experimental days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Intravenous oxytocin 0.2 IU/min during experimental days
Placebo (saline)
Intravenous saline during experimental days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 30 and 40 kg/m2 (both included)
* Percentage body fat (BF%) ≥25 for men and ≥32 for women (assessed by bioelectrical impedance analysis)
* Informed oral and written consent
Exclusion Criteria
* Alanine aminotransferase (ALT) \>2 times normal values
* History of hepatobiliary and/or gastrointestinal disorder(s)
* Kidney disease (serum creatinine above normal range and/or urine albumin-creatinine ratio (uACR) \>30 mg/g confirmed by two measures)
* Previous gastric or intestinal resection, cholecystectomy and/or any major intra-abdominal surgery (including bariatric surgery)
* Previous pancreatic disease and/or neoplasia
* Regular tobacco smoking and/or use of other nicotine products
* Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment
* Pituitary gland disorders
* Initiation of special diets, lifestyle changes and/or weight loss \>5% of total body weight within three months prior to or during study period
* Pregnancy or breastfeeding
* Long QTc on electrocardiogram (ECG) at screening (≥0.45 seconds for men and ≥0.46 seconds for women)
* Any physical or psychological condition or ongoing medication the investigator group suspect would interfere with trial participation
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Filip Krag Knop
Professor, MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Clinical Metabolisk Research
Hellerup, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-23059585
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.